search button
Open Access

EPAC1 overexpression is a prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer

  • Authors:
    • Ding-Ping Sun
    • Chia-Lang Fang
    • Han-Kun Chen
    • Kuo-Shan Wen
    • You-Cheng Hseu
    • Shih-Ting Hung
    • Yih-Huei Uen
    • Kai-Yuan Lin

  • View Affiliations

  • Published online on: February 14, 2017     https://doi.org/10.3892/or.2017.5442
  • Pages: 1953-1960

  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

cAMP signaling controls a variety of cellular functions. In addition to the well-known signal transducer cAMP-dependent protein kinase, a more recently discovered transducer is the exchange protein directly activated by cAMP (EPAC). EPAC responses are mediated by small G proteins, which regulate biologic functions such as cell adhesion, migration and proliferation. Recently, the clinical importance of EPAC1 has received increased attention. This study investigated the correlations between the expression of EPAC1 and various clinicopathologic parameters as well as the survival of the patients with gastric cancer (GC). The patient cohort in this study consisted of 141 cases of GC that presented from 1999 through 2011; documented clinicopathologic parameters and clinical outcomes were available for all cases. Immunoblotting, immunohistochemistry and quantitative real-time PCR were used to examine EPAC1 expression in gastric cells and tissues. siRNA technology was used to study the effect of EPAC1 knockdown on cell proliferation and invasion. An increase in EPAC1 expression was found in GC cells and tissues. The overexpression of EPAC1 was associated with the depth of invasion (P=0.0021), stage (P=0.0429), and vascular invasion (P=0.0049) and was correlated with poor disease-free survival (P=0.0029) and overall survival (P=0.0024). A univariate Cox regression analysis showed that the overexpression of EPAC1 was a prognostic marker for GC (P=0.038). Furthermore, cell studies indicated that the knockdown of EPAC1 in GC cells suppressed cell proliferation and invasion. The overexpression of EPAC1 can be used as a marker to predict the outcome of patients with GC, and EPAC1 represents a potential therapeutic modality for treating GC.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 37 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Sun D, Fang C, Chen H, Wen K, Hseu Y, Hung S, Uen Y and Lin K: EPAC1 overexpression is a prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer. Oncol Rep 37: 1953-1960, 2017
APA
Sun, D., Fang, C., Chen, H., Wen, K., Hseu, Y., Hung, S. ... Lin, K. (2017). EPAC1 overexpression is a prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer. Oncology Reports, 37, 1953-1960. https://doi.org/10.3892/or.2017.5442
MLA
Sun, D., Fang, C., Chen, H., Wen, K., Hseu, Y., Hung, S., Uen, Y., Lin, K."EPAC1 overexpression is a prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer". Oncology Reports 37.4 (2017): 1953-1960.
Chicago
Sun, D., Fang, C., Chen, H., Wen, K., Hseu, Y., Hung, S., Uen, Y., Lin, K."EPAC1 overexpression is a prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer". Oncology Reports 37, no. 4 (2017): 1953-1960. https://doi.org/10.3892/or.2017.5442